DVA Price Prediction Next Week
Technical Analysis: DVA is currently trading at $172.55 in pre-market with RSI(14) at 61.78, indicating a moderately overbought condition. The 20-day SMA stands at $169.83, with price above this level suggesting short-term bullish momentum.
Fibonacci Analysis: Current price is between Fibonacci R1 ($178.64) and Pivot ($174.72), suggesting immediate resistance ahead. Support levels are identified at $170.81 (S1) and $168.40 (S2).
News Impact: Recent options activity shows significant put volume at $110 strike for December 2026, indicating some long-term bearish sentiment. However, DVA is listed among holdings with downside potential in VOO ETF, suggesting institutional concerns.
Price Prediction for Next Week: Based on technical indicators and Fibonacci levels:
- Bullish Scenario (60% probability): Price likely to test R1 at $178.64
- Bearish Scenario (40% probability): May retrace to S1 at $170.81
Target Price Range: $170.81 - $178.64
Recommendation: SELL
- Current pre-market price ($172.55) is near resistance
- RSI showing overbought conditions
- Significant put options activity suggesting downside risks
- Exit target: $174.72 (Fibonacci pivot)
- Stop loss: $178.64 (R1 level)
DVA Similar Chart Price Prediction
The price of DVA is predicted to go up -8.43%, based on the high correlation periods with AWI. The similarity of these two price pattern on the periods is 98.94%.
DVA
AWI
Down: -8.43%Similarity: 98.94%
DVA Revenue Forecast
DVA EPS Forecast
DVA FAQs
What is bull’s view on DVA?
What is bear's view on DVA?
What is DVA revenue forecast for next quarter？
What is DVA eps forecast for next quarter？
DVA VS S&P500
Excluding recent COVID-19 mortality challenges and obesity drug expansion, the ESRD patient population may grow at a healthy rate in the U.S. and around the globe for the long run, which should benefit DaVita.
DaVita enjoys top-tier status in the essential dialysis business, and we do not expect competitive dynamics to negatively affect that attractive position anytime soon.
While growing at-home care could change its business model a bit, DaVita could also benefit from ESRD patients being able to continue working and staying on commercial insurance plans.
DVA Analyst's Forecast
Andrew Mok
Barclays
Hold
2024-10-31
Price Target
$150 → $164
Upside
+17.3%
Barclays analyst Andrew Mok raised the firm's price target on DaVita to $164 from $150 and keeps an Equal Weight rating on the shares. The company reported a narrow EBIT beat and absorbed $10M-$20M of Q4 supply chain impact in its unchanged guidance, the analyst tells investors in a research note.
David Macdonald
Truist Securities
Hold
2024-10-07
Price Target
$165 → $175
Upside
+11.08%
